Ocumension Therapeutics operates as an ophthalmic pharmaceutical platform company in the People's Republic of China. More Details
Adequate balance sheet with limited growth.
Share Price & News
How has Ocumension Therapeutics's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: 1477 is not significantly more volatile than the rest of Hong Kong stocks over the past 3 months, typically moving +/- 7% a week.
Volatility Over Time: 1477's weekly volatility (7%) has been stable over the past year.
7 Day Return
1 Year Return
Return vs Industry: Insufficient data to determine how 1477 performed against the Hong Kong Pharmaceuticals industry.
Return vs Market: Insufficient data to determine how 1477 performed against the Hong Kong Market.
Long-Term Price Volatility Vs. Market
How volatile is Ocumension Therapeutics's share price compared to the market and industry in the last 5 years?
Simply Wall St News
2 months ago | Simply Wall StCould The Ocumension Therapeutics (HKG:1477) Ownership Structure Tell Us Something Useful?
6 months ago | Simply Wall StWhat Kind Of Shareholders Hold The Majority In Ocumension Therapeutics' (HKG:1477) Shares?
Is Ocumension Therapeutics undervalued compared to its fair value and its price relative to the market?
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate 1477's fair value to establish if it is undervalued.
Significantly Below Fair Value: Insufficient data to calculate 1477's fair value to establish if it is undervalued.
Price To Earnings Ratio
PE vs Industry: 1477 is unprofitable, so we can't compare its PE Ratio to the HK Pharmaceuticals industry average.
PE vs Market: 1477 is unprofitable, so we can't compare its PE Ratio to the Hong Kong market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate 1477's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: 1477 is overvalued based on its PB Ratio (4.3x) compared to the HK Pharmaceuticals industry average (1.3x).
How is Ocumension Therapeutics forecast to perform in the next 1 to 3 years based on estimates from 4 analysts?
Forecasted annual revenue growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: Insufficient data to determine if 1477's forecast earnings growth is above the savings rate (1.5%).
Earnings vs Market: Insufficient data to determine if 1477's earnings are forecast to grow faster than the Hong Kong market
High Growth Earnings: Insufficient data to determine if earnings are expected to grow significantly over the next 3 years.
Revenue vs Market: 1477's revenue (84.3% per year) is forecast to grow faster than the Hong Kong market (13.3% per year).
High Growth Revenue: 1477's revenue (84.3% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: 1477 is forecast to be unprofitable in 3 years.
How has Ocumension Therapeutics performed over the past 5 years?
Last years earnings growth
Earnings and Revenue History
Quality Earnings: 1477 is currently unprofitable.
Growing Profit Margin: 1477 is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: Insufficient data to determine if 1477's year-on-year earnings growth rate was positive over the past 5 years.
Accelerating Growth: Unable to compare 1477's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: 1477 is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (2.7%).
Return on Equity
High ROE: 1477 has a negative Return on Equity (-90.51%), as it is currently unprofitable.
How is Ocumension Therapeutics's financial position?
Financial Position Analysis
Short Term Liabilities: 1477's short term assets (CN¥2.1B) exceed its short term liabilities (CN¥91.9M).
Long Term Liabilities: 1477's short term assets (CN¥2.1B) exceed its long term liabilities (CN¥5.3M).
Debt to Equity History and Analysis
Debt Level: 1477 is debt free.
Reducing Debt: 1477 had no debt 5 years ago.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: Insufficient data to determine if 1477 has enough cash runway based on its current free cash flow.
Forecast Cash Runway: Insufficient data to determine if 1477 has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.
What is Ocumension Therapeutics's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate 1477's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate 1477's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if 1477's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if 1477's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of 1477's dividend in 3 years as they are not forecast to pay a notable one for the Hong Kong market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Victor Liu (47 yo)
Mr. Ye Liu, also known as Victor, serves as Chief Executive Officer at Ocumension Therapeutics since joining on August 1, 2018 and has been its Executive Director since November 23, 2018. Mr. Liu is respon...
Experienced Management: 1477's management team is not considered experienced ( 1.3 years average tenure), which suggests a new team.
Experienced Board: 1477's board of directors are not considered experienced ( 1 years average tenure), which suggests a new board.
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: 1477 only recently listed within the past 12 months.
Ocumension Therapeutics's company bio, employee growth, exchange listings and data sources
- Name: Ocumension Therapeutics
- Ticker: 1477
- Exchange: SEHK
- Founded: 2017
- Industry: Pharmaceuticals
- Sector: Pharmaceuticals & Biotech
- Market Cap: HK$13.342b
- Shares outstanding: 619.14m
- Website: https://www.ocumension.com
Number of Employees
- Ocumension Therapeutics
- No. 1858 Yinzhongnan Road
- Guoxiang Subdistrict
- Jiangsu Province
Ocumension Therapeutics operates as an ophthalmic pharmaceutical platform company in the People's Republic of China. The company researches and develops, manufactures, and commercializes ophthalmic drugs. ...
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2021/04/11 10:18|
|End of Day Share Price||2021/04/09 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.